CN1325094C - Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method - Google Patents
Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method Download PDFInfo
- Publication number
- CN1325094C CN1325094C CNB2004100212995A CN200410021299A CN1325094C CN 1325094 C CN1325094 C CN 1325094C CN B2004100212995 A CNB2004100212995 A CN B2004100212995A CN 200410021299 A CN200410021299 A CN 200410021299A CN 1325094 C CN1325094 C CN 1325094C
- Authority
- CN
- China
- Prior art keywords
- radix
- kidney
- medicine
- clear paste
- yang
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 239000003814 drug Substances 0.000 title claims abstract description 86
- 238000000034 method Methods 0.000 title claims abstract description 12
- 229940079593 drug Drugs 0.000 title claims description 34
- 210000003734 kidney Anatomy 0.000 title abstract description 31
- 238000002360 preparation method Methods 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 20
- 239000000843 powder Substances 0.000 claims description 43
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 42
- 239000008187 granular material Substances 0.000 claims description 42
- 239000000341 volatile oil Substances 0.000 claims description 41
- 239000009636 Huang Qi Substances 0.000 claims description 32
- 241000208340 Araliaceae Species 0.000 claims description 26
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims description 26
- 235000003140 Panax quinquefolius Nutrition 0.000 claims description 26
- 235000008434 ginseng Nutrition 0.000 claims description 26
- 241001619461 Poria <basidiomycete fungus> Species 0.000 claims description 24
- 150000001875 compounds Chemical class 0.000 claims description 24
- 239000002994 raw material Substances 0.000 claims description 24
- 239000006071 cream Substances 0.000 claims description 22
- 208000037157 Azotemia Diseases 0.000 claims description 18
- 241000190633 Cordyceps Species 0.000 claims description 17
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 16
- 239000000706 filtrate Substances 0.000 claims description 14
- 208000009852 uremia Diseases 0.000 claims description 14
- 208000001647 Renal Insufficiency Diseases 0.000 claims description 12
- 201000006370 kidney failure Diseases 0.000 claims description 12
- 229920000858 Cyclodextrin Polymers 0.000 claims description 10
- 238000001291 vacuum drying Methods 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 8
- 239000000203 mixture Substances 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 238000004821 distillation Methods 0.000 claims description 6
- 239000000284 extract Substances 0.000 claims description 6
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 claims description 5
- 238000000605 extraction Methods 0.000 claims description 4
- 230000002829 reductive effect Effects 0.000 claims description 4
- 238000003756 stirring Methods 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 3
- 238000001914 filtration Methods 0.000 claims description 3
- 239000007779 soft material Substances 0.000 claims description 3
- 241000756943 Codonopsis Species 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 26
- 239000008280 blood Substances 0.000 abstract description 26
- 230000001684 chronic effect Effects 0.000 abstract description 21
- 230000000694 effects Effects 0.000 abstract description 20
- 230000006870 function Effects 0.000 abstract description 12
- 230000017531 blood circulation Effects 0.000 abstract description 11
- 210000000952 spleen Anatomy 0.000 abstract description 9
- 230000001225 therapeutic effect Effects 0.000 abstract description 7
- 230000008901 benefit Effects 0.000 abstract description 3
- 238000010792 warming Methods 0.000 abstract description 3
- 244000299790 Rheum rhabarbarum Species 0.000 abstract 1
- 235000009411 Rheum rhabarbarum Nutrition 0.000 abstract 1
- 240000007164 Salvia officinalis Species 0.000 abstract 1
- 230000003213 activating effect Effects 0.000 abstract 1
- 229940107666 astragalus root Drugs 0.000 abstract 1
- 231100000957 no side effect Toxicity 0.000 abstract 1
- 231100000956 nontoxicity Toxicity 0.000 abstract 1
- 235000005412 red sage Nutrition 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
- 241001251949 Xanthium sibiricum Species 0.000 description 53
- 241000700159 Rattus Species 0.000 description 36
- 229930024421 Adenine Natural products 0.000 description 23
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 23
- 229960000643 adenine Drugs 0.000 description 23
- 241001465754 Metazoa Species 0.000 description 22
- 208000020832 chronic kidney disease Diseases 0.000 description 12
- 230000037396 body weight Effects 0.000 description 10
- 230000008014 freezing Effects 0.000 description 9
- 238000007710 freezing Methods 0.000 description 9
- 230000001737 promoting effect Effects 0.000 description 9
- 210000002966 serum Anatomy 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 238000012360 testing method Methods 0.000 description 9
- 231100000331 toxic Toxicity 0.000 description 9
- 230000002588 toxic effect Effects 0.000 description 9
- DDRJAANPRJIHGJ-UHFFFAOYSA-N creatinine Chemical compound CN1CC(=O)NC1=N DDRJAANPRJIHGJ-UHFFFAOYSA-N 0.000 description 8
- 230000004089 microcirculation Effects 0.000 description 8
- UCTWMZQNUQWSLP-VIFPVBQESA-N (R)-adrenaline Chemical compound CNC[C@H](O)C1=CC=C(O)C(O)=C1 UCTWMZQNUQWSLP-VIFPVBQESA-N 0.000 description 7
- 229930182837 (R)-adrenaline Natural products 0.000 description 7
- 101710113174 Corticoliberin Proteins 0.000 description 7
- 208000007536 Thrombosis Diseases 0.000 description 7
- 229960005139 epinephrine Drugs 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 230000000630 rising effect Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 6
- 230000003118 histopathologic effect Effects 0.000 description 6
- 210000000265 leukocyte Anatomy 0.000 description 6
- 238000002156 mixing Methods 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 241000699670 Mus sp. Species 0.000 description 5
- 101710098398 Probable alanine aminotransferase, mitochondrial Proteins 0.000 description 5
- 101000895495 Rattus norvegicus Corticoliberin Proteins 0.000 description 5
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 5
- 208000022831 chronic renal failure syndrome Diseases 0.000 description 5
- GBONBLHJMVUBSJ-FAUHKOHMSA-N corticorelin Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(N)=O)[C@@H](C)CC)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CCSC)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H]1N(CCC1)C(=O)[C@H]1N(CCC1)C(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](N)CO)[C@@H](C)CC)[C@@H](C)O)C(C)C)C1=CNC=N1 GBONBLHJMVUBSJ-FAUHKOHMSA-N 0.000 description 5
- 210000003743 erythrocyte Anatomy 0.000 description 5
- 230000002496 gastric effect Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 230000009467 reduction Effects 0.000 description 5
- 208000004880 Polyuria Diseases 0.000 description 4
- PNNCWTXUWKENPE-UHFFFAOYSA-N [N].NC(N)=O Chemical compound [N].NC(N)=O PNNCWTXUWKENPE-UHFFFAOYSA-N 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- 229940109239 creatinine Drugs 0.000 description 4
- 230000035619 diuresis Effects 0.000 description 4
- 239000003651 drinking water Substances 0.000 description 4
- 235000020188 drinking water Nutrition 0.000 description 4
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 description 4
- 229940080345 gamma-cyclodextrin Drugs 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 210000000713 mesentery Anatomy 0.000 description 4
- 230000001473 noxious effect Effects 0.000 description 4
- 230000002265 prevention Effects 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001629 suppression Effects 0.000 description 4
- 238000003809 water extraction Methods 0.000 description 4
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 206010048469 Kidney enlargement Diseases 0.000 description 3
- 230000005856 abnormality Effects 0.000 description 3
- 210000004100 adrenal gland Anatomy 0.000 description 3
- 210000003608 fece Anatomy 0.000 description 3
- 230000003907 kidney function Effects 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 210000004072 lung Anatomy 0.000 description 3
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000031648 Body Weight Changes Diseases 0.000 description 2
- JOYRKODLDBILNP-UHFFFAOYSA-N Ethyl urethane Chemical compound CCOC(N)=O JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 description 2
- 229940043377 alpha-cyclodextrin Drugs 0.000 description 2
- 208000007502 anemia Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 238000010241 blood sampling Methods 0.000 description 2
- 230000004579 body weight change Effects 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001198 duodenum Anatomy 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- 230000002489 hematologic effect Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 231100001252 long-term toxicity Toxicity 0.000 description 2
- 230000004660 morphological change Effects 0.000 description 2
- 239000009320 niaoduqing keli Substances 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- -1 oven dry (50~75 °C) Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000012109 statistical procedure Methods 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- 208000031975 Yang Deficiency Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 230000003542 behavioural effect Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000007850 degeneration Effects 0.000 description 1
- 238000000502 dialysis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000000857 drug effect Effects 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 238000001631 haemodialysis Methods 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 210000003701 histiocyte Anatomy 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000035987 intoxication Effects 0.000 description 1
- 231100000566 intoxication Toxicity 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 230000002262 irrigation Effects 0.000 description 1
- 238000003973 irrigation Methods 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 206010025482 malaise Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 238000003305 oral gavage Methods 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 210000005085 renal fascia Anatomy 0.000 description 1
- 238000009256 replacement therapy Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000002636 symptomatic treatment Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001550 testis Anatomy 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
Group | Dosage (g/kg) | Animal (only) | Bun(mmol/L) | Crea(μmol/L) | ||
After the modeling | Administration one month | After the modeling | Administration one month | |||
Model contrast NIAODUQING Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur normal control | - 2.3 2.7 1.35 - | 8 8 8 8 8 | 18.32±3.39 △△ 18.40±1.42 18.39±2.26 18.54±2.42 3.01±0.39 | 19.28±2.86 △△ 13.56±3.01** 14.45±2.18** 17.26±3.51 3.41±0.57 | 193.75±53.85 △△ 189.13±53.02 195.13±57.30 190.63±58.36 69.38±15.50 | 214.75±56.71 117.7±24.06** 114.3±19.19** 162.25±64.65 77.88±10.60 |
Group | Dosage (g/kg) | Number of animals (n) | Hb H b (g/L) |
The big Radix Triplostegiae Grandiflorae Siberian cocklebur of normal control model contrast NIAODUQING Radix Triplostegiae Grandiflorae Siberian cocklebur is little | - - 2.30 2.70 1.35 | 8 8 8 8 8 | 127.00±12.80 69.60±8.50 △△ 76.3±9.00 ** 88.00±7.50 **+ 79.00±6.10 * |
Group | Dosage (g/kg) | Animal (only) | Bun(mmol/L) | Crea(μmol/L) | ||
After the modeling | Administration one month | After the modeling | Administration one month | |||
Model contrast NIAODUQING Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur normal control | - 2.3 2.7 1.35 0.68 - | 8 8 8 8 8 8 | 26.28±6.46 26.95±6.17 26.17±3.93 27.28±3.46 26.86±3.51 4.17±1.12 | 23.98±6.00 △△ 15.07±2.30** 14.57±2.66** 15.14±1.99** 20.56±4.86 4.64±0.94 | 644.13±69.20 639.25±97.21 645.0±93.58 643.38±67.59 636.75±83.98 79.38±12.27 | 361.63±76.82 △△ 246.25±75.0** 234.88±83.44** 249.13±63.38** 302.25±57.61 74.13±10.60 |
Group | Dosage (g/kg) | Animal (only) | Bun(mmol/L) | Crea(μmol/L) | ||
Administration 2W | 4W | Administration 2W | 4W | |||
Normal control model contrast NIAODUQING Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur | Deng capacity 2.3 2.7 1.35 0.68 | 8 8 8 8 8 8 | 4.33±1.51 29.81±5.90 △△ 21.72±6.74* 19.40±2.46** 21.51±3.43** 26.21±3.14 | 4.56±1.15 16.95±1.51 △△ 11.72±1.70** 10.17±1.97** 12.68±1.45** 14.76±1.35** | 74.88±13.61 679.25±94.40 590.25±53.40* 542.25±50.74** 592.38±68.76** 616.23±53.27 | 72.38±10.02 355.63±59.70 △△ 224.00±47.23** 208.25±51.62** 226.38±42.83** 303.38±64.84 |
Group | Dosage (g/kg) | Animal (only) | Six weeks of administration | ||
Body weight (g) | Kidney heavy (g) | Kidney coefficient (g/100g) | |||
Model contrast NIAODUQING Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur normal control | Deng capacity 2.3 2.7 1.35 0.68- | 10 10 10 10 10 10 | 168.75±22.00 △△ 206.87±29.00** 210.60±26.92** 190.60±21.62* 176.25±18.85 221.25±32.71 | 2.15±0.33 △△ 1.87±0.13* 1.77±0.19** 1.96±0.10 2.12±0.30 1.42±0.19 | 1.29±0.20 △△ 0.94±0.09** 0.85±0.08** 1.03±0.11* 1.20±0.21 0.66±0.08 |
Group | Dosage (g/kg) | Number of animals (n) | Blood viscosity (low-rate-of-shear 3/s) |
Normal control model contrast NIAODUQING | - - 2.3 | 8 8 8 | 15.39±0.69 16.64±0.78 △△ 15.25±0.65 ** |
Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur Radix Triplostegiae Grandiflorae Siberian cocklebur | 2.7 1.35 0.68 | 8 8 8 | 14.60±0.39 **+ 15.42±0.50 ** 15.68±0.63 * |
Claims (7)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100212995A CN1325094C (en) | 2004-04-14 | 2004-04-14 | Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CNB2004100212995A CN1325094C (en) | 2004-04-14 | 2004-04-14 | Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method |
Publications (2)
Publication Number | Publication Date |
---|---|
CN1682780A CN1682780A (en) | 2005-10-19 |
CN1325094C true CN1325094C (en) | 2007-07-11 |
Family
ID=35262399
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNB2004100212995A Expired - Lifetime CN1325094C (en) | 2004-04-14 | 2004-04-14 | Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN1325094C (en) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102552431A (en) * | 2012-02-17 | 2012-07-11 | 上海市中医医院 | Compositional medicine for treating contrast-induced nephropathy |
CN102698174A (en) * | 2012-07-05 | 2012-10-03 | 杨万明 | Drug for treating chronic renal failure and preparation method thereof |
CN102743594B (en) * | 2012-07-10 | 2014-01-01 | 刘金彦 | Chinese medicine composition for treating chronic renal failure |
CN102824593B (en) * | 2012-09-20 | 2014-05-07 | 杨卫彬 | Chinese patent medicine for treating chronic renal failure |
CN103720836A (en) * | 2013-12-20 | 2014-04-16 | 柳州市中医院 | Traditional Chinese medicine for treating chronic renal failure and preparation method for traditional Chinese medicine |
CN105125814B (en) * | 2015-10-19 | 2019-11-08 | 管遵信 | It is a kind of to treat chronic renal failure III, the Chinese medicine composition of IV phase |
CN105250588A (en) * | 2015-10-19 | 2016-01-20 | 陈立爱 | Chinese herbal preparation for treating kidney failure and preparation method of Chinese herbal preparation |
CN107485669A (en) * | 2017-08-18 | 2017-12-19 | 广州市圆强医药科技有限公司 | Utilize the strong raw precious treatment uremic biodialysis therapy of nephrosis |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1387872A (en) * | 2001-05-25 | 2003-01-01 | 张丰强 | Nephropathy treating medicine and its prepn |
CN1466963A (en) * | 2002-07-11 | 2004-01-14 | 山东百草药业有限公司 | Kidney relieving capsule for treating nephropathy and method for preparing the same |
-
2004
- 2004-04-14 CN CNB2004100212995A patent/CN1325094C/en not_active Expired - Lifetime
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1387872A (en) * | 2001-05-25 | 2003-01-01 | 张丰强 | Nephropathy treating medicine and its prepn |
CN1466963A (en) * | 2002-07-11 | 2004-01-14 | 山东百草药业有限公司 | Kidney relieving capsule for treating nephropathy and method for preparing the same |
Non-Patent Citations (3)
Title |
---|
尿毒清冲剂的研制与疗效观察 黄建邦 等,中药材,第17卷第5期 1994 * |
慢性肾衰竭的中草药防治研究 白善信,中国中西医结合肾病杂志,第2卷第4期 2001 * |
慢性肾衰竭的中草药防治研究 白善信,中国中西医结合肾病杂志,第2卷第4期 2001;尿毒清冲剂的研制与疗效观察 黄建邦 等,中药材,第17卷第5期 1994 * |
Also Published As
Publication number | Publication date |
---|---|
CN1682780A (en) | 2005-10-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103734428B (en) | A kind of glossy privet fruit health-care tea improving immunity and preparation method thereof | |
CN1325094C (en) | Medicine for treating uaemia and insufficiency of kidney-yang and kidney exhaustion and its preparing method | |
CN101670075B (en) | Traditional Chinese medicine composition for treating depression | |
CN103223131B (en) | Liver disease drug | |
CN1943713B (en) | A Chinese traditional medicinal composition for treating diabetes and its preparation method | |
CN100348235C (en) | Traditional Chinese medicine preparation for treating infantile diarrhea and preparation method thereof | |
CN104644967A (en) | Pharmaceutical composition for treating I-type diabetes and application thereof | |
CN104958615B (en) | A kind of Chinese medicine composition of prevention and treatment II diabetes and preparation method thereof | |
CN103977106A (en) | Traditional Chinese medicine preparation for treating nephrotic syndrome and preparation method thereof | |
CN100528186C (en) | Process for preparing Chinese medicine compound injection for treating chronic renal failure and use | |
CN110404021B (en) | Rhizoma polygonati preparation and preparation method thereof | |
CN112220846A (en) | Traditional Chinese medicine composition for treating children's chronic cough and application thereof | |
CN101874858B (en) | Traditional Chinese medicine for treating virus hepatitis and preparation method thereof | |
CN104645003A (en) | Traditional Chinese medicine preparation for treating asthma and preparation method of traditional Chinese medicine preparation | |
CN104998085A (en) | Chinese herbal compound composition capable of enhancing immune function and preparation method thereof | |
CN1212149C (en) | Cinese material medical preparation for curing children' hyperkinetic symptom and the preparation process thereof | |
CN1541692A (en) | Medicine for treating diabetes and adjusting blood sugar concentration and its preparation | |
CN104224929B (en) | A kind of Chinese medicine composition and its preparation method and application being used for the treatment of flu and upper respiratory tract infection | |
CN116942771B (en) | Traditional Chinese medicine composition for treating coronary heart disease and application thereof | |
CN100333751C (en) | Chinese traditional medicine for curing cholestatic hepatitis and preparing method | |
CN100486610C (en) | Shenkeshu capsule for treating chronic renal failure and its preparation technology | |
CN100425255C (en) | Medicine for treating cervical disease and its preparation method | |
CN106177262A (en) | One is used for treating the uremic Chinese medicine composition of nephropathy | |
CN104758796B (en) | Treat medicine of hepatic sclerosis and preparation method thereof | |
CN1274333C (en) | Kidney tonifying capsule |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: BEIJING YINKERUISI PHARMACEUTICAL TECHNOLOGY CO., Free format text: FORMER OWNER: ZHANG MINGMING ADDRESS Effective date: 20081121 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20081121 Address after: Beijing City, Xicheng District Xinfeng Street 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. Address before: D-20-10, 100 Binhe Road, Shenhe District, Shenyang, Liaoning, China Patentee before: Zhang Mingming |
|
ASS | Succession or assignment of patent right |
Owner name: BEIJING YINKERUISI PHARMACEUTICAL TECHNOLOGY CO., Free format text: FORMER OWNER: ZHANG MINGMING Effective date: 20081121 |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address after: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee after: BEIJING INCREASE PHARMACEUTICAL RESEARCH INSTITUTE Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
CP03 | Change of name, title or address | ||
CP03 | Change of name, title or address |
Address after: Double camp 102299 West Road Beijing city Changping District Science Park No. 79, No. 24 building 6 layer cloud Valley Park Patentee after: Beijing Increasepharm Co.,Ltd. Address before: 100088 Beijing city Xicheng District, New Street No. 2 Tiancheng Technology building block B room 3003 Patentee before: BEIJING INCREASE PHARMACEUTICAL INSTITUTE Co.,Ltd. |
|
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210310 Address after: No.6 Fengjing Avenue, Fengjing Industrial Park, Xi'an, Shaanxi 710300 Patentee after: XI'AN SHIJISHENGKANG PHARMACEUTICAL INDUSTRY Co.,Ltd. Address before: 102299 Beijing 6 Changping District science and Technology Park No. 79, No. 24, No. Patentee before: Beijing Increasepharm Co.,Ltd. |
|
DD01 | Delivery of document by public notice | ||
DD01 | Delivery of document by public notice |
Addressee: Hao Peiqi Document name: Notification of eligibility |
|
CX01 | Expiry of patent term | ||
CX01 | Expiry of patent term |
Granted publication date: 20070711 |
|
DD01 | Delivery of document by public notice |
Addressee: Hao Peiqi Document name: Notice of Termination of Patent Rights |
|
DD01 | Delivery of document by public notice |